1 / 32

Managing the acute coronary syndrome: What is new?

Master Class : Advanced CV Risk management in cardiology June 17-18, 2011, London. Presentation topic. Managing the acute coronary syndrome: What is new?. Slide lecture prepared and held by:. Prof. Adam Timmis Barts and the London School of Medicine and Dentistry

jalena
Download Presentation

Managing the acute coronary syndrome: What is new?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MasterClass: Advanced CV Risk management in cardiology June 17-18,2011, London Presentation topic Managing the acute coronary syndrome: What is new? Slide lecture prepared and held by: Prof. Adam Timmis Bartsand the London School of Medicineand Dentistry University of London

  2. Declining incidence of Myocardial InfarctionAge-sex-adjusted data from Kaiser Permanente CA Any MI NSTEMI STEMI

  3. Potential drivers of reduced AMI rates Rates of diabetes in patients with 1st AMI MINAP data • Life-style and risk factors? • ↓ smoking • ↑ diabetes, diagnosed hypertension, dyslipidaemia Outpatient medication use prior to AMI Kaiser Permanente data CA • Medication use? • ↑ all preventive medication B-blocker ACE-ARB

  4. What about revascularisation? PTCA vs medical: Cardiac death or myocardial infarction Katritsis, D. G. et al. Circulation 2005 • PCI? “88% of patients believed that PCI would reduce their risk for MI, and 82% believed that it would reduce their risk for death” Rothberg MB et al. Ann Intern Med 2010 Stable angina NSTEMI - 18/12 after RCA, LAD grafts • CABG? Assessment of the angiographic severity of coronary stenosis is inadequate to accurately predict the time or location of a subsequent coronary occlusion Little et al. Circulation 1988

  5. Summary 1. • Rates of AMI declining • Likely consequence of life-style and treatment factors • Revasc non-contributory

  6. Life Saving Strategies in AMI • Prevent pre-hospital death from 1° VF • get the patient to a defibrillator ASAP • Prevent hospital death from heart failure • initiate reperfusion therapy ASAP • Prevent late deaths from • Recurrent ischaemic events • 2° prevention therapy • Lethal arrhythmias • implantable defibrillator

  7. 1st episode of VF/1000 pts/hr 33% of people who die from AMI do so before they reach hospital Sayer J Heart 2002

  8. Components of pre-hospital delay in STEMI Frequency distributions using MINAP data for 2004-2005 • Time to call for help accounts for most of the variation in pre-hospital delay. Culprits • Older people (>70 yrs) • Women • People with diabetes • Pain onset in early hours • Pain at w/e

  9. BHF Doubt Kills Campaign ended October 2007 the message!

  10. Summary 2. • 33% of all AMI deaths occur out-of-hospital • Shortening the time to call for help the single most important way to save lives in AMI • Public awareness campaigns never been shown to work

  11. Life Saving Strategies in AMI • Prevent pre-hospital death from 1° VF • get the patient to a defibrillator ASAP • Prevent hospital death from heart failure and cardiogenic shock • initiate reperfusion therapy ASAP • Prevent late deaths from • Recurrent ischaemic events • 2° prevention therapy • Lethal arrhythmias • implantable defibrillator

  12. STEMI: reperfusion therapy Primary PCI • Adjunctive Antiplatelet • Therapy • Aspirin 300mg • Clopidogrel 600mg • ± Abciximab

  13. 10.3 (10.0-10.7) 2.9 (2.8-3.1) Impact of door to balloon timeACC-NCDR Cath PCI Registry: 2005-2006 (n=43,801) Rathore BMJ (2010)

  14. Culprit only vs complete revascularisation in STEMI: meta-analysis J Thromb Thrombolysis 2011 • Complete Revasc • No benefit for mortality • No benefit for recurrent MI • Reduced need for repeat revasc

  15. DES vs BMS for primary PCI: meta-analysis of RCTs (n=2786) HR: 0.80 (0.48-1.39) HR: 0.38 (0.29-0.50) Kastrati A et al. Eur Heart J 2007;28:2706-2713

  16. Dual antiplatelet therapy (DAPT) - continue for 12 months after DES • Refining aspirin/clopidogrel treatment regimens to protect against late thrombosis • Prolonged DAPT for >12 months No effect on 2 yr event rates Park S-J et al. N Engl J Med 2010 • Titrate clopidogrel dose against platelet function testing No effect on 6 month event rates GRAVITAS Investigators. JAMA 2011 • Adjust clopidogrel dose according to genotype • Clopidogrelprodrug activated in liver by cytochrome P-450 (CYP) enzymes Carriers of loss-of-function CYP alleles have same event rates as non-carriers • Paré G, et al. N Engl J Med 2010

  17. New Inhibitors of the platelet the ADP P2Y12 receptor

  18. PLATO: ticagrelor vs clopidogrel in ACS (n=18624) Wallentin L et al. N Engl J Med 2009 Reduced risk of CV events with no increase in bleeding risk

  19. 1° PCI: 1 year mortality by baseline CRP and adjunctive treatment with abciximab or placebo. Pooled analysis of 4 ISAAR trials (n=4847) Iijima R et al. Heart 2009;

  20. NSTEMI: emergency treatment PCI: moderate high risk 1. Aspirin + clopidogrel ± GP IIb/IIIa inhibitor 2. LMWH - now fondaparinux (factor Xa inhibitor) 3. Anti-ischaemic drugs (BB, nitrates) 4. ± Angiography ± PCI

  21. NSTEMI Non-MI ACS STEMI Chest Pain ?cause Probability of dying Days after presentation NSTEMI: don’t under-estimate it Prognosis: poor Undertreated

  22. Trials of Invasive vs Conservative Treatment Strategy in NSTEMI O’Donoghue, M. et al. JAMA 2008;300:71-80

  23. Routine Versus Selective Invasive Strategy in NSTEMI Meta-Analysis of Individual Patient Data (n=5467) CV Death or MI Time to 1st Revasc Procedure Fox, K. A. A. et al. J Am Coll Cardiol 2010

  24. Life Saving Strategies in AMI • Prevent pre-hospital death from 1° VF • get the patient to a defibrillator ASAP • Prevent hospital death from heart failure and cardiogenic shock • initiate reperfusion therapy ASAP • Prevent late deaths from • Recurrent ischaemic events • 2° prevention therapy • Lethal arrhythmias • implantable defibrillator

  25. 0.1 1 0.08 2 0.06 0.04 3 0.02 4 0 0 180 360 Days after discharge from hospital Adjusted KM curves: 1 yr survival by number of 2° prevention drugs MINAP discharge data NSTEMI and STEMI 2003-2009

  26. Hazard ratio (95% CI) for death Impact of under-utilisation: adjusted HRs (95% CI) for death by discharge regimens that exclude key 2° prevention drugs MINAP discharge data NSTEMI and STEMI 2003-2009

  27. GPRD: Continuing statin therapy in 12m post ACS N=6607 linked GPRD-MINAP records

  28. Discontinuation of clopidogrel(“non-compliance”) after discharge from hospital Linked MINAP-GPRD registries (n=8445) • Median Duration of therapy: 12m • Hazard of death/AMI • clopidogrel vs no clopidogrel HR 0.57 (0.50-0.65) • discontinuation vs continuation HR 2.62 (2.17-3.17)

  29. Summary 4. • 2° prevention therapy - additive beneficial effects on survival • diminishing efficacy probably caused by non-adherence to treatment in primary care • non-adherence to clopidogrel in linked GPRD-MINAP registries more than doubles the risk of recurrent myocardial infarction or death during the first year.

  30. Life Saving Strategies in AMI • Prevent pre-hospital death from 1° VF • get the patient to a defibrillator ASAP • Prevent hospital death from heart failure and cardiogenic shock • initiate reperfusion therapy ASAP • Prevent late deaths from • Recurrent ischaemic events • 2° prevention therapy • Lethal arrhythmias • implantable defibrillator

  31. Implantable defibrillator post AMI NICE 2007 2° prevention • Late cardiac arrest VT/VF • Sustained VT with syncope • Sustained VT and LV ejection fraction <35% 1° prevention • AMI >4 weeks previously • LV ejection fraction <30% and QRS >120msec • LV ejection fraction <35% and non-sustained VT on Holter

  32. The revolution for coronary outcomes in east London How it was Thrombolysis 2° prevention 1° PCI

More Related